Free Trial

MetLife (MET) Stock Forecast & Price Target

MetLife logo
$82.41 +1.08 (+1.33%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$81.79 -0.62 (-0.75%)
As of 10/3/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
2
Buy
11

Based on 13 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 2 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for MET.

Consensus Price Target

$94.64
14.83% Upside
According to the 13 analysts' twelve-month price targets for MetLife, the average price target is $94.64. The highest price target for MET is $103.00, while the lowest price target for MET is $84.00. The average price target represents a forecasted upside of 14.83% from the current price of $82.41.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MET Analyst Ratings Over Time

TypeCurrent Forecast
10/4/24 to 10/4/25
1 Month Ago
9/4/24 to 9/4/25
3 Months Ago
7/6/24 to 7/6/25
1 Year Ago
10/5/23 to 10/4/24
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$94.64$95.60$94.17$86.00
Forecasted Upside14.83% Upside16.96% Upside18.45% Upside2.33% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesS&P 500
Consensus Rating Score
2.92
2.31
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside14.83% Upside20.76% Upside10.49% Upside
News Sentiment Rating
Neutral News

See Recent MET News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B)
9/19/2025Piper Sandler
2 of 5 stars
John Barnidge
John Barnidge
Not Rated
DowngradeOverweightNeutral$84.00+6.16%
9/16/2025Wolfe Research
3 of 5 stars
Tracy Benguigui
Not Rated
UpgradeStrong-Buy
8/22/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
8/18/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$98.00 ➝ $94.00+21.99%
8/11/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$100.00 ➝ $103.00+35.08%
8/11/2025Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$94.00 ➝ $92.00+20.66%
8/7/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$94.00 ➝ $91.00+23.65%
7/10/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$94.00 ➝ $97.00+23.76%
7/8/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$86.00 ➝ $95.00+18.68%
7/7/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$88.00 ➝ $94.00+18.63%
1/23/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$97.00+13.09%
11/27/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$97.00 ➝ $99.00+11.50%
8/1/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$99.00 ➝ $96.00+24.92%
7/23/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$83.00 ➝ $89.00+18.26%
5/22/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$77.00 ➝ $80.00+9.50%
1/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralBuy$70.00 ➝ $80.00+16.08%
10/4/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$71.00+18.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:21 AM ET.


Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 1, 2025. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • The current stock price is around $80, which may present a buying opportunity for investors looking for value in the financial services sector.
  • MetLife, Inc. has received a "strong-buy" rating from analysts, indicating strong confidence in the company's future performance.
  • The company recently announced a quarterly dividend of $0.5675 per share, translating to an annualized dividend yield of 2.8%, which can provide a steady income stream for investors.
  • Analysts predict that MetLife, Inc. will post earnings per share of 9.65 for the current fiscal year, suggesting potential growth in profitability.
  • With a market capitalization of approximately $53.32 billion, MetLife, Inc. is a significant player in the financial services industry, which may offer stability and resilience in various market conditions.

MetLife
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • The company reported earnings per share of $2.02 for the last quarter, missing the consensus estimate by $0.30, which may raise concerns about its short-term performance.
  • MetLife, Inc. experienced a decline in quarterly revenue, down 2.7% compared to the same quarter last year, indicating potential challenges in maintaining growth.
  • Analysts have recently adjusted their price targets downward, with some lowering their expectations for the stock's future performance.
  • The company's debt-to-equity ratio stands at 0.57, which, while manageable, indicates that it has a moderate level of debt that could impact financial flexibility.
  • Market volatility and economic uncertainties could pose risks to MetLife, Inc.'s business operations and profitability, making it a less attractive investment in turbulent times.

MET Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $94.64, with a high forecast of $103.00 and a low forecast of $84.00.

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 14.83% based on their 12-month stock forecasts.

Over the previous 90 days, MetLife's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.


This page (NYSE:MET) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners